ibogaine has been researched along with naloxone in 12 studies
| Studies (ibogaine) | Trials (ibogaine) | Recent Studies (post-2010) (ibogaine) | Studies (naloxone) | Trials (naloxone) | Recent Studies (post-2010) (naloxone) |
|---|---|---|---|---|---|
| 445 | 8 | 136 | 20,134 | 1,257 | 3,321 |
| Protein | Taxonomy | ibogaine (IC50) | naloxone (IC50) |
|---|---|---|---|
| Cytochrome P450 2D6 | Homo sapiens (human) | 2 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.043 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0219 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.0397 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.1896 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.05 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.0795 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.0154 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0089 | |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | 0.0055 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (75.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cros, J; Francés, B; Gout, R; Zajac, JM | 1 |
| Jaffe, J; Sharpe, L | 1 |
| Jaffe, JH; Sharpe, LG | 1 |
| Benveniste, M; Fossom, LH; Geter-Douglass, B; Layer, RT; Popik, P; Skolnick, P; Witkin, JM | 1 |
| Codd, EE | 1 |
| Glick, SD; Herrick-Davis, K; Pearl, SM; Teitler, M | 1 |
| Cappendijk, SL; Dzoljic, MR; Fekkes, D | 1 |
| Berger, SP; Broderick, PA; Hsu, K; Reid, MS; Souza, KH | 1 |
| Mash, DC; Pablo, JP | 1 |
| Burton, P; Kim, JA; McDonald, RV; Parke, LA; Siegel, S | 1 |
| Willyard, C | 1 |
| Ameer, B; Howes, JF; Maillet, EL; Mash, DC; Prou, D | 1 |
12 other study(ies) available for ibogaine and naloxone
| Article | Year |
|---|---|
Effects of ibogaine on naloxone-precipitated withdrawal in morphine-dependent mice.
Topics: Animals; Drug Synergism; Ibogaine; Mice; Morphine; Morphine Dependence; Naloxone; Pain Measurement; Substance Withdrawal Syndrome | 1992 |
Ibogaine fails to reduce naloxone-precipitated withdrawal in the morphine dependent rat.
Topics: Animals; Ibogaine; Morphine Dependence; Naloxone; Rats; Substance Withdrawal Syndrome | 1990 |
Ibogaine fails to reduce naloxone-precipitated withdrawal in the morphine-dependent rat.
Topics: Animals; Behavior, Animal; Grooming; Ibogaine; Male; Morphine Dependence; Naloxone; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome; Tremor | 1990 |
NMDA antagonist properties of the putative antiaddictive drug, ibogaine.
Topics: Animals; Cerebellum; Dizocilpine Maleate; Electric Conductivity; Excitatory Amino Acid Antagonists; Hippocampus; Ibogaine; Male; Mice; Naloxone; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substance Withdrawal Syndrome; Substance-Related Disorders | 1995 |
High affinity ibogaine binding to a mu opioid agonist site.
Topics: Animals; Binding Sites; Ibogaine; Kinetics; Male; Mice; Mice, Inbred Strains; Morphine; Naloxone; Prosencephalon; Receptors, Opioid, mu; Tritium | 1995 |
Radioligand-binding study of noribogaine, a likely metabolite of ibogaine.
Topics: Analgesics; Animals; Benzeneacetamides; Cattle; Cerebral Cortex; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, D-Penicillamine (2,5)-; Enkephalins; Ibogaine; In Vitro Techniques; Kinetics; Naloxone; Pyrrolidines; Radioligand Assay; Receptors, Opioid | 1995 |
The inhibitory effect of norharman on morphine withdrawal syndrome in rats: comparison with ibogaine.
Topics: Animals; Arousal; Brain; Carbolines; Harmine; Ibogaine; Male; Morphine; Naloxone; Rats; Rats, Wistar; Receptors, Opioid; Substance Withdrawal Syndrome | 1994 |
Neuropharmacological characterization of local ibogaine effects on dopamine release.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Ibogaine; Male; Microdialysis; Naloxone; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa | 1996 |
Noribogaine stimulates naloxone-sensitive [35S]GTPgammaS binding.
Topics: Animals; Binding, Competitive; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Guanosine 5'-O-(3-Thiotriphosphate); Ibogaine; Logistic Models; Male; Naloxone; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; Stimulation, Chemical; Sulfur Radioisotopes | 1998 |
Ibogaine interferes with motivational and somatic effects of naloxone-precipitated withdrawal from acutely administered morphine.
Topics: Animals; Conditioning, Psychological; Drug Administration Schedule; Excitatory Amino Acid Antagonists; Ibogaine; Male; Morphine; Motivation; Naloxone; Narcotic Antagonists; Narcotics; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome | 2002 |
Pharmacotherapy: Quest for the quitting pill.
Topics: Animals; Behavior, Addictive; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Clinical Trials as Topic; Cocaine-Related Disorders; Counseling; Dopamine; Drug Discovery; Drug Industry; Humans; Ibogaine; Lobeline; Molecular Targeted Therapy; Naloxone; Naltrexone; Oligopeptides; Opioid-Related Disorders; Pleasure; Rats; Receptors, Nicotinic; Reward; Substance-Related Disorders; Tobacco Use Disorder; Vaccines; Vesicular Monoamine Transport Proteins | 2015 |
Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents.
Topics: Administration, Oral; Animals; Brain; Dose-Response Relationship, Drug; Ibogaine; Male; Mice; Morphine; Naloxone; Rats; Rats, Sprague-Dawley; Retrospective Studies; Rodentia; Substance Withdrawal Syndrome | 2016 |